Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Class A and Class B Common Stock Class A and Class B Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Shares, beginning of period (in shares) at Jan. 31, 2022		270,451,615
Balance, beginning of period at Jan. 31, 2022	$ 1,650,788	$ 27	$ 2,271,980	$ 454	$ (621,673)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)		7,650,525
Issuance of common stock upon exercise of options	17,335	$ 1	17,334
Vesting of restricted stock units (in shares)		1,303,854
Issuance of common stock under employee stock purchase plan (in shares)		1,335,183
Issuance of common stock under employee stock purchase plan	19,159	$ 0	19,159
Cancellation of holdback shares		(9,551)
Vesting of early exercised options	103		103
Issuance of common stock in connection with Attivo acquisition (in shares)		6,032,231
Issuance of common stock in connection with acquisition	186,333	$ 1	186,332
Stock-based compensation	168,486		168,486
Other comprehensive loss	(6,821)			(6,821)
Net loss	(378,678)				(378,678)
Shares, end of period (in shares) at Jan. 31, 2023		286,763,857
Balance, end of period at Jan. 31, 2023	1,656,705	$ 29	2,663,394	(6,367)	(1,000,351)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)		10,298,114
Issuance of common stock upon exercise of options	28,318	$ 1	28,317
Vesting of restricted stock units (in shares)		6,021,877
Issuance of common stock under employee stock purchase plan (in shares)		1,607,874
Issuance of common stock under employee stock purchase plan	19,147		19,147
Vesting of early exercised options	186		186
Stock-based compensation	223,563		223,563
Other comprehensive loss	4,817			4,817
Net loss	(338,693)				(338,693)
Shares, end of period (in shares) at Jan. 31, 2024		304,691,722
Balance, end of period at Jan. 31, 2024	1,594,043	$ 30	2,934,607	(1,550)	(1,339,044)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)		7,881,544
Issuance of common stock upon exercise of options	33,406	$ 1	33,405
Vesting of restricted stock units (in shares)		9,370,381
Issuance of common stock under employee stock purchase plan (in shares)		1,300,151
Issuance of common stock under employee stock purchase plan	$ 22,500		22,500
Stock Repurchased During Period, Shares	(19,300)
Issuance of common stock in connection with Attivo acquisition (in shares)		2,354,607
Issuance of common stock in connection with acquisition	$ 23,739	$ 1	23,738
Stock-based compensation	280,292		280,292
Other comprehensive loss	3,708			3,708
Net loss	(288,441)				(288,441)
Shares, end of period (in shares) at Jan. 31, 2025		325,579,105
Balance, end of period at Jan. 31, 2025	$ 1,669,247	$ 32	$ 3,294,542	$ 2,158	$ (1,627,485)